肺炎支原体疫苗候选抗原的研究进展  

Advances in research on candidate antigens of Mycoplasma pneumoniae vaccine

作　　者：李双丽 朱文勇[1] 廖国阳[1] 

机构地区：[1]中国医学科学院北京协和医学院医学生物学研究所云南省重大传染病疫苗研发重点实验室,云南昆明650118

出　　处：《中国生物制品学杂志》2017年第10期1107-1110,共4页Chinese Journal of Biologicals

摘　　要：肺炎支原体(Mycoplasma pneumoniae,MP)是社区获得性肺炎的主要病原菌,其可引起人类的呼吸道感染,从而导致部分人群出现过敏性哮喘;MP亦可加重肺部疾病,引起一些并发症。目前,治疗MP感染使用最多的为大环内酯类抗生素,随着抗生素类药物的广泛应用,出现耐大环内酯抗生素肺炎支原体(macrolide-resistant MP,MRMP)的流行,耐药率高达90%,且尚无详细的治疗方案。因此,MP疫苗对预防和控制MP感染十分必要。本文就MP疫苗候选抗原中的全菌体抗原、蛋白抗原及糖脂抗原的研究进展作一综述。Mycoplasma pneumonia（MP） is the main pathogen of community-acquired pneumonia, which may cause respiratory infection in humans, resulting in anaphylactic asthma in partial population. MP may also aggravate lung diseases and cause some complications. At present, MP infection is mainly treated with macrolide antibiotics. However,with the wide application of antibiotics, the epidemic of macrolide-resistant MP（MRMP） appeared, with a resistance rate of 90%, to which no protocol of therapy has been developed. For this reason, MP vaccine is very important to prevent and control MP infection. In this paper, the research on whole cell antigen, protein antigen and glycolipid antigen in candidate MP vaccine antigen are summarized.

关 键 词：肺炎支原体 疫苗 抗原 

分 类 号：R375.2[医药卫生—病原生物学] R392-33[医药卫生—基础医学]